Anne E. White - 10 Feb 2025 Form 4 Insider Report for ELI LILLY & Co (LLY)

Reporting relationship
EVP & Pres, Lilly Neuroscience
Issuer ticker
LLY
Reported as of
10 Feb 2025
Net transaction value
+$5,933,469
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
12 Feb 2025, 16:29:27 UTC
Prior SEC filing
04 Feb 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jonathan Groff for Anne E. White, pursuant to authorization on file

Key filing fact

Anne E. White filed Form 4 for ELI LILLY & Co (LLY) on 12 Feb 2025.

Key facts

  • This page summarizes Anne E. White's Form 4 filing for ELI LILLY & Co (LLY).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 12 Feb 2025, 16:29.

Change

  • Previous filing in this sequence was filed on 04 Feb 2025.
  • Current net transaction value: +$5,933,469.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LLY transaction

Common Stock

Award

Transaction value
$5,933,469
Shares
+6,829
Change %
+10%
Price
$868.88
Shares after
74,210
Date
10 Feb 2025
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LLY transaction Derivative

Restricted Stock Unit

Award

Transaction value
$0
Shares
+3,572
Change %
Price
$0.000000
Shares after
3,572
Date
10 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,572
Exercise price
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .